Ozempic and Vision Loss: What You Need to Know
Ozempic (semaglutide) is a GLP-1 receptor agonist manufactured by Novo Nordisk, approved by the FDA in 2017 for the treatment of type 2 diabetes. It is administered as a weekly subcutaneous injection. By 2024, Ozempic had become one of the best-selling pharmaceutical drugs in history, with tens of millions of prescriptions filled annually in the United States.
A landmark study published in JAMA Ophthalmology in July 2024 by researchers at Harvard Medical School's Mass Eye and Ear found that patients taking semaglutide (the active ingredient in both Ozempic and Wegovy) had a 4.28x higher risk of developing NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) compared to patients taking other diabetes medications.
What is Ozempic?
Ozempic contains semaglutide — a synthetic analog of glucagon-like peptide-1 (GLP-1), a hormone naturally produced in the gut. When injected, it:
- Stimulates insulin release in response to elevated blood glucose
- Suppresses glucagon (the hormone that raises blood sugar)
- Slows gastric emptying (food moves through the stomach more slowly)
- Reduces appetite through central nervous system effects
Ozempic is approved for type 2 diabetes. Its sister drug Wegovy uses a higher dose of the same semaglutide molecule for weight management.
The NAION Connection
NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) is a sudden loss of blood supply to the optic nerve, causing rapid and typically permanent vision loss. The Harvard study hypothesized several mechanisms by which semaglutide might increase NAION risk:
- GLP-1 receptors are present in the eye and optic nerve — the drug may directly affect optic nerve vasculature
- Rapid and significant changes in blood pressure or fluid dynamics during treatment may affect optic nerve perfusion
- Metabolic changes affecting microvascular blood flow to the optic disc
The exact biological mechanism is an active area of research. The epidemiological association from the Harvard study, however, is striking and has been widely cited in the medical literature.
Ozempic Lawsuits: Key Allegations
Plaintiffs filing Ozempic NAION lawsuits allege:
- Failure to warn: Novo Nordisk did not include NAION as a potential adverse event on Ozempic's US label, despite scientific evidence of the risk
- Negligence: The company failed to conduct adequate post-market safety surveillance for optic nerve adverse events
- Fraud: Marketing materials presented an incomplete picture of Ozempic's safety profile
- Strict liability: The drug is unreasonably dangerous given the undisclosed NAION risk
MDL 3163: Where Are Ozempic Vision Cases?
Ozempic NAION lawsuits are being consolidated in MDL 3163, filed in the Eastern District of Pennsylvania before Judge Karen Marston. The MDL leadership was appointed in March 2026. This MDL covers both Ozempic and other GLP-1 drugs from Novo Nordisk and Eli Lilly.
Who Qualifies for an Ozempic Vision Loss Lawsuit?
To qualify for an Ozempic NAION claim, you generally need:
- A documented prescription for Ozempic (or generic semaglutide)
- A diagnosis of NAION by an ophthalmologist, confirmed by eye examination and visual field testing
- NAION developed during or after Ozempic use
- No prior NAION diagnosis before starting Ozempic
- Filing within your state's statute of limitations
Ozempic Vision Loss Symptoms
If you experienced any of the following after starting Ozempic, consult an ophthalmologist immediately:
- Sudden vision loss or blurriness in one eye, especially upon waking
- Loss of a portion of your visual field (altitudinal defect)
- Reduced color vision in one eye
- Painless visual disturbance (distinguishing from optic neuritis, which causes eye pain)
- Difficulty reading or recognizing faces on one side